ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on Twitter

Kidney Week

Abstract: SA-PO790

Association of Serum Uric Acid With Hypertension Severity and Adverse Cardiac Changes at Baseline in Youth With Primary Hypertension

Session Information

  • Hypertension and CVD: Mechanisms
    November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
    Abstract Time: 10:00 AM - 12:00 PM

Category: Hypertension and CVD

  • 1503 Hypertension and CVD: Mechanisms

Authors

  • Vincent, Carol, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
  • Chen, Ashton, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
  • South, Andrew M., Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States
Background

Mechanisms driving hypertension (HTN)-related organ damage in youth with HTN are incompletely understood. Uric acid may be associated with HTN and related target organ damage in youth, but this relationship remains paradoxical due in part to methodological limitations.

Methods

This is a secondary analysis of data from a pilot prospective cohort study of youth aged 5–17 years with newly diagnosed primary HTN defined by the AAP Clinical Practice Guideline. Exclusion criteria were diabetes mellitus, chronic kidney disease, heart disease, or non-English or Spanish speaker. Our exposures were serum uric acid (SUA) and SUA standard deviation (SD) from the mean. Our outcomes were blood pressure (BP), BP z-score, left ventricular mass index (LVMI) indexed to height and BSA, and relative wall thickness (RWT). We estimated associations between exposures and outcomes with generalized linear models adjusted for gestational age, birth weight, sex, and body mass index as identified in a directed cyclic graph.

Results

Of the 30 participants, mean age was 13.4 years (SD 3.6) with 30% female, 27% Black or African American, and 40% Hispanic or Spanish origin ethnicity. Median SUA was 5.4 mg/dL [IQR 4.9, 7.1]. No participants had left ventricular hypertrophy. Elevated blood pressure was seen in 10%, stage 1 hypertension in 47%, and stage 2 hypertension in 27% of the population. In adjusted analyses, SUA from mean was not associated with systolic BP (β 0.18, 95% CL -2.72 to 3.08), diastolic BP (β -1.72, 95% CL -4.35 to 0.92), LVMI g/m2.7 (β -0.72, 95% CL -3.08 to 1.64), LVMI g/BSA (β -0.61, 95% CL -4.52 to 5.75), or RWT (β -1.77, 95% CL -9.62 to 6.07). SUA was associated with Diastolic BP z-score (β -0.38, 95% CL -0.61 to 0.15).

Conclusion

We did not observe associations of SUA with HTN or related heart changes on echocardiogram. Our findings could be reflect that our population did not have LVH or our small sample size. Ongoing analyses include investigating associations of renin-angiotensin system with target organ damage.

Funding

  • Other NIH Support